Stem definition | Drug id | CAS RN |
---|---|---|
4921 | 133865-89-1 |
Dose | Unit | Route |
---|---|---|
75 | mg | O |
Property | Value | Reference |
---|---|---|
Vd (Volume of distribution) | 2.19 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 1.17 mL/min/kg | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 21.67 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Sept. 20, 2019 | PMDA | Meiji Seika Pharma Co., Ltd. | |
March 21, 2017 | FDA | NEWRON PHARMS US INC | |
Dec. 18, 2014 | EMA | Zambon SpA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Dyskinesia | 73.46 | 50.67 | 21 | 371 | 28904 | 46656766 |
Parkinsonism hyperpyrexia syndrome | 60.99 | 50.67 | 8 | 384 | 165 | 46685505 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|
Source | Code | Description |
---|---|---|
ATC | N04BD03 | NERVOUS SYSTEM ANTI-PARKINSON DRUGS DOPAMINERGIC AGENTS Monoamine oxidase B inhibitors |
FDA MoA | N0000175761 | Monoamine Oxidase-B Inhibitors |
FDA EPC | N0000175762 | Monoamine Oxidase Type B Inhibitor |
FDA MoA | N0000190113 | Breast Cancer Resistance Protein Inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Parkinson's disease | indication | 49049000 | DOID:14330 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 12.92 | acidic |
pKa2 | 7.54 | Basic |
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
100MG | XADAGO | MDD US | N207145 | March 21, 2017 | RX | TABLET | ORAL | March 21, 2022 | NEW CHEMICAL ENTITY |
50MG | XADAGO | MDD US | N207145 | March 21, 2017 | RX | TABLET | ORAL | March 21, 2022 | NEW CHEMICAL ENTITY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Amine oxidase [flavin-containing] B | Enzyme | INHIBITOR | Ki | 6.35 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
Sodium channel protein type 9 subunit alpha | Ion channel | IC50 | 4.48 | CHEMBL | |||||
Amine oxidase [flavin-containing] A | Enzyme | IC50 | 4.35 | CHEMBL | |||||
Amine oxidase [flavin-containing] B | Enzyme | IC50 | 7.59 | CHEMBL | |||||
Sodium channel alpha subunits; brain (Types I, II, III) | Ion channel | IC50 | 5.09 | CHEMBL | |||||
Sigma non-opioid intracellular receptor 1 | Membrane receptor | IC50 | 7.71 | CHEMBL |
ID | Source |
---|---|
D10158 | KEGG_DRUG |
202825-46-5 | SECONDARY_CAS_RN |
4036707 | VANDF |
C1098261 | UMLSCUI |
CHEBI:134718 | CHEBI |
SAG | PDB_CHEM_ID |
CHEMBL48582 | ChEMBL_ID |
CHEMBL396778 | ChEMBL_ID |
131682 | PUBCHEM_CID |
8291 | IUPHAR_LIGAND_ID |
C092797 | MESH_SUPPLEMENTAL_RECORD_UI |
8013 | INN_ID |
DB06654 | DRUGBANK_ID |
90ENL74SIG | UNII |
1922448 | RXNORM |
241367 | MMSL |
d08444 | MMSL |
016557 | NDDF |
016558 | NDDF |
718852000 | SNOMEDCT_US |
763521008 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Xadago | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27505-110 | TABLET, FILM COATED | 50 mg | ORAL | NDA | 31 sections |
Xadago | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27505-111 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 31 sections |